Interchangeable Biosimilars May Qualify For ‘Immediate Substitution’ In Medicare Part D
Proposed policy could help promote uptake of interchangeable biosimilars to AbbVie’s blockbuster Humira. However, some PBMs and insurers are not persuaded that interchangeability is a useful distinction so may not rush to take advantage of the new flexibility.
